SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 43.65 |
| Enterprise Value ($M) | 13.95 |
| Book Value ($M) | 42.88 |
| Book Value / Share | 1.63 |
| Price / Book | 1.02 |
| NCAV ($M) | 40.77 |
| NCAV / Share | 1.55 |
| Price / NCAV | 1.07 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.49 |
| Return on Assets (ROA) | -0.22 |
| Return on Equity (ROE) | -0.44 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 6.39 |
| Current Ratio | 6.39 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 90.17 |
| Assets | 92.28 |
| Liabilities | 49.41 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Novo Holdings A/S | 0.00 | -100.00 | |
| 13G/A | Redmile Group, LLC | 7.90 | -26.34 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 4,006 | 36,402 | 11.00 | |
| 782 | 36,437 | 2.15 | |
| 12,815 | 63,499 | 20.18 | |
| 993 | 22,625 | 4.39 | |
| 1,224 | 29,832 | 4.10 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| KRYS – Krystal Biotech, Inc. | KURA – Kura Oncology, Inc. |
| KYTX – Kyverna Therapeutics, Inc. | LXRX – Lexicon Pharmaceuticals, Inc. |
| LYEL – Lyell Immunopharma, Inc. |
Financial data and stock pages provided by
Fintel.io